A

Accellacare | DuPage Medical Group

Research site

(Unclaimed)

Location

430 Warrenville Road, Suite B, Lisle, Illinois, United States of America

Site insights

Top conditions

Top treatments

Cetrelimab

TAR-200

Sasanlimab

Cisplatin

Gemcitabine

Parent organization

This site is a part of Accellacare

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 5 total trials

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder canc...

Active, not recruiting

Non-muscle Invasive Bladder Cancer

Drug: Bacillus Calmette-Guerin

Drug: PF-06801591

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting

Urinary Bladder Neoplasms

Drug: Cisplatin

Radiation: Hypo-fractioned radiation therapy

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Active, not recruiting

Urinary Bladder Neoplasms

Drug: TAR-200

Biological: Cetrelimab

Locations recently updated

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants wi...

Enrolling

High-Risk Non-Muscle-Invasive Bladder Cancer

Drug: Cretostimogene Grenadenorepvec

Trial sponsors

C

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms